Caris Molecular Intelligence and Chemotherapy for Cancer

Caris Molecular Intelligence – a step towards individual chemotherapy for cancer

Caris Molecular Intelligence™ involves the analysis of a tumor sample at the molecular level, enabling physicians to select the chemotherapy drugs that are most suitable for effective cancer treatment in a particular individual patient.

Chemotherapy can have a different effect on cancer in each individual clinical case.

The Caris Molecular oncology test is carried out at molecular level. Its aim is to identify tumor biomarkers (or ‘indicators’) that together create the tumor’s unique ‘fingerprint’.

Caris Molecular Intelligence gives physicians the opportunity to select an individual plan of chemotherapy, based on the structural features of the tumor, for each cancer patient.

This analysis is particularly relevant in the treatment of rare, aggressive and metastatic cancers.


Caris Molecular Intelligence molecular analysis is applicable to all types of solid tumors, particularly in cases:

  • where the standard approaches to cancer treatments proved ineffective
  • when the range of known treatment methods is not large enough
  • where there are rare, aggressive and metastatic tumor types

Caris Life Sciences has performed molecular testing for more than 70,000 patients worldwide.

Among the completed tests, the following types of diseases were highlighted:

metastatic breast cancer, bladder cancer, cholangiocellular cancer, colon cancer, extrahepatic biliary tract cancer, malignant tumors of female genital tract, stomach cancer, gastroesophageal adenocarcinoma, glioblastoma, gastrointestinal stromal tumor, cancers of the head and neck cancer, kidney cancer, liver cancer, lung cancer, malignant tumor of male genital tract, melanoma, neuroendocrine tumor, oligodendroglioma, ovarian cancer, pancreatic cancer, malignant tumors of the pituitary, retroperitoneal or peritoneal carcinoma, peritoneal or retroperitoneal sarcoma, and malignant tumors of the small intestine, soft tissue tumor, thymus cancer, thyroid carcinoma, uveal melanoma.

With Caris Molecular Intelligence, over 6,000 doctors from 58 countries were able to solve the problem of cancer treatment selection for more than 70,000 patients suffering from cancers of 150 different histologic subtypes.



Caris Molecular Intelligence is performed on tissue samples obtained during surgical removal of the tumor or collected during the biopsy.

As tumor biomarkers may change over time and under the influence of drugs, it is better to use the ‘freshest’ sample for the study. Nevertheless, older samples can be tested if new ones cannot be obtained.


The MI Profile Report includes test results, recommendations for a chemotherapy treatment plan for the individual cancer, data on the drugs for the chemotherapy (potentially effective or ineffective) and additional clinical data in summarized and simplified form. The report is sent directly from Amaxa to the attending doctor.



Testing technology

Caris Life Sciences uses advanced testing technology to identify and carefully scrutinize each tumor marker…